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Effective delivery of oxygen and nutrients is mandatory for proper development of mammalian embryos.1 Although 
initially supported by molecular diffusion only, around day 8 of 
gestation (E8), the mouse embryo starts relying in full on blood 
circulation to further develop. By this time, heart starts beating and 
extraembryonic yolk sac blood islands, that is, mesoderm-derived 
clusters of hematopoietic cells surrounded by a layer of endothe-
lial cells (EnCs), coalesce to form a vascular network filled with 
large nucleated primitive erythroblasts.2 This allows vital mol-
ecules to diffuse from the maternal blood, which is contained in 
giant trophoblast cell-lined uterine sinuses, into visceral yolk sac 
blood vessels that directly connect to the embryonic vasculature. 
Between E12.5 and E14.5, the mature chorioallantoic placenta 
progressively replaces the yolk sac as main nutrient exchange 
organ supporting the development of the mouse embryo.3
Large embryonic blood vessels and the vasculature of several 
embryonic organs and extraembryonic yolk sac initially arise by 
vasculogenesis, namely, the differentiation of angioblasts into 
EnCs that self-assemble in a homogeneously-sized primitive 
vascular plexus.1 The latter is then remodeled by angiogenesis 
into a hierarchically sized mature vascular tree that facilitates 
and optimizes the distribution of blood.1 In this context, EnC 
mechanosensitive adhesion receptors translate blood fluid shear 
traction forces into biochemical signals that allow vascular 
remodeling and maturation.4 Although it is well established that 
extraembryonic EnCs do not contribute to intraembryonic blood 
vessels, the molecular mechanisms that differentially regulate 
yolk sac and embryonic vascularization are poorly defined.1
Sema3 (class 3 semaphorins) are secreted guidance cues 
that in the developing embryo signal through the cytosolic 
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Objective—Molecular pathways governing blood vessel patterning are vital to vertebrate development. Because of their 
ability to counteract proangiogenic factors, antiangiogenic secreted Sema3 (class 3 semaphorins) control embryonic 
vascular morphogenesis. However, if and how Sema3 may play a role in the control of extraembryonic vascular 
development is presently unknown.
Approach and Results—By characterizing genetically modified mice, here, we show that surprisingly Sema3F acts instead as a 
selective extraembryonic, but not intraembryonic proangiogenic cue. Both in vivo and in vitro, in visceral yolk sac epithelial 
cells, Sema3F signals to inhibit the phosphorylation-dependent degradation of Myc, a transcription factor that drives the 
expression of proangiogenic genes, such as the microRNA cluster 17/92. In Sema3f-null yolk sacs, the transcription of 
Myc-regulated microRNA 17/92 cluster members is impaired, and the synthesis of Myc and microRNA 17/92 foremost 
antiangiogenic target Thbs1 (thrombospondin 1) is increased, whereas Vegf (vascular endothelial growth factor) signaling is 
inhibited in yolk sac endothelial cells. Consistently, exogenous recombinant Sema3F inhibits the phosphorylation-dependent 
degradation of Myc and the synthesis of Thbs1 in mouse F9 teratocarcinoma stem cells that were in vitro differentiated in 
visceral yolk sac epithelial cells. Sema3f−/− mice placentas are also highly anemic and abnormally vascularized.
Conclusions—Sema3F functions as an unconventional Sema3 that promotes extraembryonic angiogenesis by inhibiting the 
Myc-regulated synthesis of Thbs1 in visceral yolk sac epithelial cells.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2017;37: 
1710-1721. DOI: 10.1161/ATVBAHA.117.308226.)
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GAP (GTPase-activating protein) domain of Plexin receptors5 
to inhibit R-Ras, M-Ras, and Rap1, 3 small GTPases that are 
crucial positive regulators of integrin-mediated cell adhesion 
in different cell types, EnC included.6,7 The chemorepulsive 
activity of Sema3A8–10 and Sema3E11 was previously reported 
to control the vascular patterning in chick, zebrafish, and mouse 
embryos.12 In addition, thanks to their ability to inhibit angio-
genesis, both Sema3A and Sema3E exert an effective antican-
cer activity.13,14 Similarly, Sema3F was also found to display 
powerful antiangiogenic and antitumor effects13,14; however, if 
and how Sema3F may play a role in embryonic vascular devel-
opment is unknown. Surprisingly, at odds with the antiangio-
genic function of all other Sema3 proteins, here we unveil how 
Sema3F drives a Myc-dependent proangiogenic program that 
is selectively restricted to the extraembryonic vasculature. In 
addition to shedding light on the molecular mechanisms that 
selectively drive extraembryonic but not embryonic blood 
vessel formation, our findings also suggest how an aberrant 
expression of Sema3F might be involved in placenta vascular 
malformations.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Targeted Disruption of Mouse Sema3f Gene Results 
in Partially Penetrant Embryonic Lethality but 
Does Not Control Embryonic Vascular Development
To understand whether Sema3F may control both embryonic 
and postnatal mouse development, we characterized and 
compared Sema3f- and, for control purposes, Sema3a-null 
mice.8 Heterozygous Sema3a and Sema3f mice were phe-
notypically normal and fertile. As expected,8 the percentage 
of born Sema3a-null mice was also much lower than the 
Mendelian ratio (5.7% Sema3a−/−, 39.1% Sema3a+/+, 55.2% 
Sema3a+/−; n=460). Similarly, Walz et al15 already described 
that Sema3f−/− mice were born significantly less (14%) than 
that predicted by Mendelian ratio. As shown in Table 1, 
we confirmed that the frequency of born Sema3f-knockout 
pups is indeed lower than expected (5.7% Sema3f−/−, 29.4% 
Sema3f+/+, 64.9% Sema3f+/−; n=465). The higher embry-
onic lethality we observed in our Sema3f−/− mice compared 
with that reported by Walz et al15 might be likely because 
of differences in the percentage of C57Bl/6 and 129P2/
OlaHsd genetic backgrounds between the 2 colonies (see 
Materials and Methods and Figure I in the online-only Data 
Supplement). Thus, similarly to Sema3a−/− mice, most of 
Sema3f-null mice also die in utero.
To assess the timing of embryolethality, we geno-
typed embryos collected at different developmental stages. 
Between E9.5 and E10.5, a clear significant decrease in 
Sema3f- and Sema3a-null embryos emerged. In particu-
lar, the Sema3f-null embryos were 19.6% at E9.5 (n=249) 
and 13.5% at E10.5 (n=81), whereas those of Sema3a-null 
embryos were 18.6% at E9.5 (n=285) and 15.2% at E10.5 
(n=105). No gross phenotypic differences were present 
in the few outliving Sema3f- or Sema3a-knockout mice. 
However, as previously reported,16 if matched with wild-
type mice of the same litter, 3-week-old Sema3a−/− mice 
were smaller in size, their weight was halved, and they had 
difficulty maintaining an upright posture.
Sema3A signaling was previously reported to con-
trol vascular morphogenesis in zebrafish,9 chick,10 and 
mouse embryos.8,17–19 We hence investigated whether, 
similar to Sema3A, Sema3F may also regulate mouse 
embryonic angiogenesis. We examined by fluorescence 
confocal microscopy the vasculature of whole-mount 
endomucin-stained wild type (Figure 1A through 1D), 
Sema3f-null (Figure 1F through 1I), and Sema3a-null 
(Figure 1K through 1N) embryos at E9.5. Compared 
with control littermates (Figure 1E), Sema3f- knock-
out embryos (Figure 1J) displayed retarded growth (E9.5 
wild-type embryos: 21.2±0.5 somites; E9.5 Sema3f−/− 
embryos: 18.8±0.5 somites; Table 2) but not major vas-
cular defects (Figure 1A through 1D and 1F through 1I). 
In agreement with previous studies8 and differently from 




Fbw7 F-box and WD repeat domain-containing 7
GAP GTPase-activating protein
PYS parietal yolk sac
rSEMA3F recombinant semaphorin 3F
SNAIL1 snail family transcriptional repressor 1
Thbs1 thrombospondin 1
VYS visceral yolk sac
Table 1. Genotypes of the Offspring Generated From Sema3f and Sema3a Heterozygous Intercrosses on a C57BL/6 Background
Sema3f Sema3a
 Total +/+ +/− −/−  Total +/+ +/− −/−
Term pups 465 29.4% (137) 64.9% (302) 5.7% (26) Term pups 460 39.1% (180) 55.2% (254) 5.7% (26)
E9.5 249 27.7% (69) 32.1% (80) 19.6% (49) E9.5 285 30.2% (86) 51.2% (146) 18.6% (53)
E10.5 81 40.7% (33) 45.6% (37) 13.5% (11) E10.5 105 32.4% (34) 52.4% (55) 15.2% (16)
Heterozygous Sema3a and Sema3f mice were intercrossed, and the progeny was analyzed. Only 5.7% adult knockout mice were observed after genotyping the 
offspring of both Sema3f+/− (n=465) and Sema3a+/− (n=460) mating, respectively. Timed mating revealed an embryonic lethality between E9.5 and E10.5 in both Sema3f 
and Sema3a mutants. A percentage of 19.6 (n=249) at E9.5 and 13.5 (n=81) at E10.5 was observed in the progeny of Sema3f intercrosses and a percentage of 18.6 
(n=285) at E9.5 and 15.2 (n=105) at E10.5 was observed in the progeny of Sema3a. Sema3 indicates class 3 semaphorin.
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Sema3f-null embryos (Figure 1J), Sema3a-knockout 
embryos (Figure 1O) displayed an even stronger growth 
retardation (E9.5 Sema3a−/− embryos: 17±1.2 somites, n=7; 
Figure 1O) that was associated with angiogenic remodel-
ing defects (Figure 1K through 1N). The cephalic plexus 
of wild-type (Figure 1B and 1C) and Sema3f−/− (Figure 1G 
and 1H), but not Sema3a−/− E9.5 embryos (Figure 1L and 
1M), was stereotypically reshaped into a pattern wherein 
cephalic veins were discernible. Moreover, in E9.5 wild-
type (Figure 1D) and Sema3f-null (Figure 1I) but not 
Sema3a-null (Figure 1N) embryos, the dorsal longitudinal 
anastomotical vessel started to be remodeled into a mature 
perineural capillary plexus.
Sema3F Drives Extraembryonic Angiogenesis
In quest of explanations for the growth retardation associated 
with an essentially normal vascular development of Sema3f- 
knockout embryos, we reasoned that it may be due to defective 
angiogenesis in extraembryonic organs, namely, yolk sac and 
placenta. Accordingly, we observed that, although yolk sacs 
of E10.5 wild-type embryos contained a dense hierarchically 
ordered vascular network (Figure 1P, 1Q, 1V, and 1W), Sema3f-
null yolk sacs unexpectedly displayed a dramatic reduction in 
blood vessel number and organization into a mature vascular 
tree (Figure 1R, 1S, 1X, and 1Y). Sema3f −/− mice placentas 
were also highly anemic and abnormally vascularized (Results 
section; Discussion section, and Figure II in the online-only 
Figure 1. Sema3 (class 3 semaphorin)-A is necessary for embryonic angiogenic remodeling, whereas Sema3F is required for yolk sac 
blood vessel formation. Whole-mount endomucin stained E9.5 wild-type (A through D), Sema3f−/− (F through I), and Sema3a−/− (K through 
N) embryos. The cephalic plexus of wild-type (B and C) and Sema3f−/− (G and H) but not Sema3a−/− (L and M) embryos is remodeled to 
give rise to easily distinguishable cephalic veins. The cephalic perineural vascular plexus develops through remodeling of the dorsal longi-
tudinal anastomotical vessel in wild-type (D) and Sema3f−/− (I) but not in Sema3a−/− embryos (N). E, J, and O, Stereomicroscopic analyses 
reveals how, when compared with age-matched wild-type embryos (E), the development of both Sema3f−/− (J) and Sema3a−/− (O) E9.5 
embryos is delayed. Developmental delay is more severe in Sema3a−/− (O) than that in Sema3f−/− (J) embryos. B, G, and L, Magnifications 
of the top boxed areas in (A), (F), and (K), respectively. C, H, and M, Magnifications of the boxed areas in (B), (G), and (L), respectively. D, 
I, and N, Magnifications of the bottom boxed areas in (A), (F), and (K), respectively. Scale bars, 300 μm (A, F, and K) and 100 μm (E, J, 
and O). Stereomicroscopy (P through U) and endomucin-staining confocal microscopy (V through AA) analyses of E10.5 wild-type (P, Q, 
V, and W), Sema3f−/− (R, S, X, and Y) and Sema3a−/− (T, U, Z, and AA) yolk sacs. When compared with wild-type yolk sacs (P, Q, V, and 
W), a dramatic decrease in blood vessels is observed in Sema3f−/− yolk sacs (R, S, X, and Y), while a poorly remodeled primary capillary 
plexus and the persistence of some blood islands characterize Sema3a−/− (T, U, Z, and AA) yolk sacs. Q, S, U, W, Y, and AA, Magnifica-
tions of (P), (R), (T), (V), (X), and (Z), respectively. Scale bars, 100 μm (P, R, and T) and 150 μm (V, X, and Z).
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Data Supplement). A not remodeled primary vascular plexus 
and occasional scattered blood islands were instead present in 
Sema3a-null yolk sacs (Figure 1T, 1U, 1Z, and 1AA).
The mouse yolk sac consists of mesoderm-derived blood 
islands and vessels that are positioned between endoderm-
derived visceral yolk sac (VYS) epithelial cell (EpC) layer 
and parietal yolk sac (PYS) EpC layer.20 VYS EpCs control 
nutrient and gas exchanges and the development of blood 
islands and vessels; PYS EpCs instead protect the embryo.20 
To understand which cell types synthesize Sema3F and 
express the major Sema3F coreceptor Nrp2, we performed 
confocal microscopy analyses on E9.5 yolk sacs that were 
double stained with either anti-Sema3F or anti-Nrp2 and 
antibodies recognizing vascular EnC or VYS EpC or PYS 
EpC markers, respectively, represented by endomucin, 
cytokeratin 8/18 (CK8/18), and Snail1 proteins.21 Sema3F 
protein was present in VYS EpCs and in part also in vas-
cular EnCs of Sema3f+/+ but not in Sema3f−/− yolk sacs 
(Figure 2A and 2C). PYS EpCs essentially do not produce 
Sema3F (Figure 2A and 2C). We next analyzed the expres-
sion of Sema3F in E9.5 embryos. As illustrated in Figure 
IIIC and IIID in the online-only Data Supplement, Sema3F 
was mainly expressed in vascular EnCs of both wild-type 
and Sema3a−/−, but not in Sema3f−/−, embryos. Similarly, 
Sema3A was expressed in endomucin+ vessels of Sema3f−/− 
yolk sacks (Figure IIIA and IIIB in the online-only Data 
Supplement).
We also observed that Nrp2, the major Sema3F corecep-
tor, is expressed in VYS EpCs and vascular EnCs but not in 
PYS EpCs (Figure 2B and 2D). Thus, in the yolk sac, Nrp2-
expressing EnCs and VYS EpCs may be stimulated by para-
crine/autocrine Sema3F.
Table 2. Number of Intersomitic Vessels Evaluated in Sema3f, 


















P=0.0062 (n=6) P=0.0039 (n=7) P=0.0015 (n=3)
All data are expressed as mean±SEM. Sema3 indicates class 3 semaphorin.
Figure 2. Sema3 (class 3 semaphorin)-F and Nrp2 are mainly expressed by the CK8/18 (cytokeratin 8/18)+ epithelial cells of the yolk sac. 
Frozen sections of yolk sacs were decorated for Sema3F (red) in costaining alternatively with endomucin, CK8/18, or Snail1 antibodies 
(green) and Dapi (4′,6-diamidino-2-phenylindole; blue). A, Sema3F largely colocalized with the CK8/18 visceral epithelial cells marker. As 
expected, no Sema3F expression was detected in Sema3f−/− samples. B, Confocal analysis showed that in both Sema3f+/+ and Sema3f−/− 
mice, Nrp2 is greater expressed by the visceral yolk sac as assessed by Nrp2-CK8/18 costaining. Confocal analysis was performed on 
tissue sections from 6 mice per group; scale bars, 100 μm. C and D, Graphs show the percentage of Sema3F and Nrp2 colocalization 
with endomucin, CK8/18, and Snail1 in both Sema3f+/+ and Sema3f−/− yolk sacs (**P<0.01, Student t test).
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Sema3F Signaling Inhibits the Degradation 
of Myc Transcription Factor in Visceral 
Yolk Sac Epithelial Cells
Our data indicate that, at odds with its well-characterized anti-
angiogenic effects reported in the adult animal,13 Sema3F plays 
a proangiogenic role in extraembryonic tissues. Because it is 
well documented that in EnCs Sema3F elicits canonical antian-
giogenic signals,22 we considered the option that Sema3F might 
exert its proangiogenic activity at least in part by controlling 
gene transcription in extraembryonic tissues, for example, by 
acting on Nrp2-expressing VYS EpCs. In this regard, the basic 
helix-loop-helix transcription factor Myc is a well-established 
regulator of vascular development,23 and in Caenorhabditis ele-
gans, a Myc-like network was found to cooperate with sema-
phorin signaling in the control of cell migration.24 Hence, we 
first assessed whether the loss of Sema3f was associated with 
the modulation of yolk sac Myc protein expression. Confocal 
immunofluorescence analysis on E9.5 wild-type and Sema3f−/− 
yolk sacs revealed how Myc protein was decreased by 0.73-
fold in Sema3f-knockout animals (Figure 3A and 3B).
Myc protein stability is regulated by phosphorylation 
and ubiquitin-dependent degradation. In particular, GSK3 
(glycogen synthase kinase 3)-mediated phosphorylation 
of Myc at Thr58 gives rise to a binding site that is directly 
recognized by the E3 ubiquitin ligase Fbw7(F-box and WD 
repeat domain-containing 7), resulting in ubiquitination fol-
lowed by proteasomal degradation of Myc.25 Consistent with 
previous in vitro data,25 we found that in E9.5 Sema3f−/− yolk 
sacs the reduction in Myc protein amount was associated with 
a selective increase of Myc Thr58 phosphorylation in VYS 
EpCs, but neither in PYS EpCs nor in EnCs (Figure 3C and 
3D). Altogether, our findings support a model in which in the 
mouse yolk sac paracrine/autocrine Sema3F signals to inhibit 
the (GSK3-dependent) phosphorylation on Thr58 and ensu-
ing degradation of the proangiogenic Myc transcription fac-
tor in VYS EpCs. Hence, paracrine/autocrine Sema3F signals 
inhibit the phosphorylation on Thr58 and ensuing degradation 
of Myc in VYS EpCs.
Sema3F Promotes the Transcription of Myc-
Regulated AngiomiRs in the Mouse Yolk Sac
Myc may drive yolk sac blood vessel development down-
stream of Sema3F signaling by promoting the transcription 
of different proangiogenic genes.23,26 In particular, it was 
Figure 3. Sema3 (class 3 semaphorin)-F activates a Myc- and miR-18a/miR-19b–dependent proangiogenic pathway in the mouse 
yolk sac. A and B, Quantification of immunofluorescence analysis of E9.5 yolk sacs using Myc antibody (red) counterstained with Dapi 
(4′,6-diamidino-2-phenylindole; blue) showed that Myc expression decreases by 0.73-fold in Sema3f−/− yolk sacs. C and D, Myc phos-
phorylation at Thr58 significantly increased in E9.5 Sema3f−/− yolk sacs compared with the wild type. Furthermore, a double staining 
with anti-p-Myc (Thr58) and either anti-endomucin or anti–cytokeratin 8/18 (CK8/18), or anti-Snail1 revealed that p-Myc (Thr58) is mainly 
expressed in CK8/18+ visceral yolk sac epithelial cells, whereas only few amounts of Thbs1 were associated with endomucin+ vascular 
endothelial cells. E, Real-time polymerase chain reaction revealed how, compared with wild-type yolk sacs, proangiogenic miR-18a and 
miR-19b diminished in Sema3f−/− yolk sacs. (***P<0.0001; **P<0.01; *P<0.05, Student t test). Scale bars, 100 μm.
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reported that in cultured embryonic stem cells, Myc loss 
impairs Vegfa (vascular endothelial growth factor A) gene 
expression.23 However, even if Myc protein abundance was 
dramatically decreased (Figure 3A and 3B), we did not detect 
any significant reduction of Vegfa mRNA in Sema3f-null yolk 
sacs, as evaluated by real-time quantitative polymerase chain 
reaction (Figure IVA in the online-only Data Supplement). 
These findings indicate that in the mouse yolk sac, Sema3F 
should induce the transcription of additional Myc-dependent 
proangiogenic genes other than Vegfa.
Specific miRNA genes, dubbed angiomiRs, are master 
regulators of developmental angiogenesis and transcription 
of the key proangiogenic miR-17/92 cluster26 lies under the 
control of Myc.27 Thus, we considered the possibility that Myc 
protein downmodulation in Sema3f−/− yolk sacs may impair 
miR-17/92 gene cluster transcription. By real-time quantita-
tive polymerase chain reaction, we analyzed the transcription 
of genes belonging to miR-17/92 cluster in E9.5 wild-type and 
Sema3f −/− yolk sacs. Among miR-17/92 gene cluster mem-
bers, miR-18a and miR-19b-1 emerged as the most modulated 
miRNAs in Sema3f −/− yolk sacs. Compared with wild type, 
miR-18a and miR-19b-1 levels, respectively, decreased by 
0.5- and 0.8-fold in Sema3f −/− yolk sacs (Figure 3E). Hence, 
Sema3F signaling drives the Myc-mediated transcription of 
the proangiogenic miR 17/92 cluster members miR-18a and 
miR-19b-1.
Sema3F Inhibits the Expression of the 
Antiangiogenic Factor Thbs1 (Thrombospondin 
1) in Mouse Visceral Yolk Sac Epithelial Cells
Thbs1 (thrombospondin 1) is an effective angiogenesis inhibi-
tor28 whose expression is inhibited by Myc protein23 and Myc-
induced miR-17/92 cluster miRNAs,29 in particular, miR-18a 
and miR-19b-1.30–32 To assess whether Thbs1 expression was 
modulated in E9.5 Sema3f −/− yolk sacs compared with their 
wild-type counterpart, we first analyzed Thbs1 gene tran-
scription by real-time quantitative polymerase chain reaction 
(Figure IVB in the online-only Data Supplement). Compared 
with wild-type yolk sacs, Thbs1 mRNA levels increased by 
1.5-fold in Sema3f −/− yolk sacs. Next, we assessed Thbs1 pro-
tein expression by confocal immunofluorescence microscopy. 
Quantitave analysis revealed that, in comparison to wild-type 
Figure 4. Sema3 (class 3 semaphorin)-F signaling inhibits Thbs1 (thrombospondin 1) protein expression. A and B, Quantification of immuno-
fluorescence analyses of E9.5 yolk sacs showed that Thbs1 expression increases by 2.5-fold in Sema3f−/− yolk sacs. Scale bars, 300 μm  
(**P<0.001; ***P<0.0001, Student t test). C, Confocal analysis showed that Thbs1 protein expression is enriched in CK8/18 (cytokeratin 
8/18)+ visceral yolk sac epithelial cells compared with the other cell types. Scale bars, 100 μm. D, Bar graph shows the percentage of 
Thbs1 colocalization with endomucin, CK8/18, and Snail1 in both wild-type and Sema3f−/− yolk sacs (**P<0.001, Student t test).
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yolk sacs, Thbs1-positive areas increased by 2.5-fold in 
Sema3f −/− yolk sacs (Figure 4A and 4B).
To understand which cell type(s) synthesize Thbs1, we 
analyzed by confocal microscopy E9.5 yolk sacs that were 
double stained with anti-Thbs1 and either antiendomucin 
or anti-CK8/18, or anti-Snail1. We detected Thbs1 protein 
mainly in CK8/18+ VYS EpCs, whereas only a few amount 
of Thbs1 was associated with endomucin+ vascular EnCs 
(Figure 4C and 4D). Of note, we did not observe any differ-
ence in the expression of Thbs2 in the different cell types of 
Sema3f−/−, compared with wild-type yolk sacs (Figure V in the 
online-only Data Supplement).
It has been clearly documented how Thbs1 effectively 
impairs VEGFA function mostly by inhibiting VEGF-R2 
(VEGF receptor 2 phosphorylation).28,33,34 Therefore, we inves-
tigated whether endothelial VEGF signaling may be affected 
in Sema3f-knockout yolk sacs and uncovered that indeed tyro-
sine phosphorylation VEGF-R2 was reduced dramatically in 
vascular EnCs of E9.5 Sema3f −/− yolk sacs (Figure 5). Hence, 
in Sema3f-null yolk sacs, VYS EpCs synthesize high amount 
of Thbs1 protein that in turn effectively impairs VEGF-R2 
activation in vascular EnCs.
In In Vitro Differentiated VYS EpCs, Exogenous 
Recombinant Sema3F Inhibits the Myc-Dependent 
Expression of the Antiangiogenic Factor Thbs1
To directly assess whether Sema3F may stimulate Myc pro-
tein accumulation and the decrease of the antiangiogenic fac-
tor Thbs1, we set up an in vitro system to create differentiated 
CK8/18+ VYS Eps that may then be treated with recombi-
nant Sema3F (rSema3F). To this aim, we exploited the well-
characterized in vitro model of F9 testicular teratocarcinoma 
stem cells that, when cultured as aggregates in suspension and 
stimulated with retinoic acid, differentiate in VYS Eps.35,36 
Fluorescent confocal microscopy confirmed that, similar to 
what observed in the mouse yolk sac (Figure 2B and 2D), in 
vitro differentiated CK8/18+ VYS EpCs expressed Sema3F 
receptor Nrp2 as well (Figure 6A). Of note, quantitative 
analysis of immunofluorescent staining revealed how exog-
enously added rSema3F effectively inhibits the degradative 
GSK-dependent phosphorylation of Myc on Thr58 (Figure 6B 
and 6D) and increases total Myc protein levels (Figure 6B and 
6D), while significantly decreasing Thbs1 (Figure 6C and 6D), 
whose expression is known to be inhibited by Myc.23 Thus, 
direct in vitro stimulation of cultured VYS Eps with rSema3F 
promotes the accumulation of Myc and impairs the expression 
of the antiangiogenic factor Thbs1.
Sema3a Sema3f Double Knockdown Results 
in Early Mouse Embryonic Lethality 
and Severely Impairs Both Embryonic 
and Extraembryonic Angiogenesis
To understand whether Sema3A and Sema3F may cooperate in 
regulating embryonic development, we first mated Sema3a+/− 
and Sema3f+/− mice to create double Sema3a+/− Sema3f+/− 
mice that in F1 progeny were born in a normal Mendelian 
ratio. Then, to generate double Sema3a/Sema3f-knockout 
mice, Sema3a+/− Sema3f+/− animals were mated. Among 405 
weaned mice, no double Sema3a−/− Sema3f −/− mice were born. 
These data indicate that all double Sema3a Sema3f-knockout 
mice died in utero. To assess the time of embryo lethality, dou-
ble Sema3a−/− Sema3f −/− embryos were genotyped at different 
gestation times, observing a large loss of double Sema3a−/− 
Sema3f −/− embryos around E9.5 (Table 3).
Compared with wild-type animals (Figure 7D), Sema3a−/− 
Sema3f −/− embryos were significantly smaller (Figure 7H), 
Figure 5. Sema3f-knockout impairs VEGF-R2 (vascular endothelial growth factor receptor R2) phosphorylation in the yolk sac. A, Confo-
cal microscopy analysis showed that VEGF-R2 phosphorylation is strongly reduced in Sema3f−/− yolk sacs compared with wild-type con-
trols, whereas VEGF-R2 expression is not affected. Scale bars, 100 μm. B, Percentage of p-VEGF-R2 and total VEGF-R2 relative levels in 
endomucin+ endothelial cell. (***P<0.0001, Student t test). Sema3 indicates class 3 semaphorin.
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and their growth delay at E9.5 was more important than 
that observed in Sema3a−/− embryos (Figure 1O). In fact, on 
average, at E9.5, Sema3a−/− Sema3f −/− embryos displayed 11 
somites compared with the 21 somites of wild-type litter-
mates (Table 2). Confocal immunofluorescence microscopy 
on whole-mount endomucin-stained Sema3a−/− Sema3f −/− 
embryos (Figure 7E through 7G) unveiled how vascular abnor-
malities were considerably more severe than those observed 
in Sema3a-null mice (Figure 1K through 1N). In particular, 
compared with wild-type embryos (Figure 7A through 7C), 
both cephalic vascular plexus (Figure 7E and 7F) and interso-
mitic blood vessels (Figure 7E and 7G) were poorly formed 
and, when formed, they were not remodeled. Short noninter-
connected sprouts enclosed wide avascular spaces. Next, we 
evaluated the impact of Sema3a Sema3f-double knockout on 
yolk sac vascularization. Because of the difficulties in recov-
ering viable double Sema3a−/− Sema3f−/− mutant embryos at 
E10.5, we decided to analyze the vasculature of E9.5 yolk 
sacs, which, differently from wild-type yolk sacs (Figure 7I), 
appeared extremely pale and essentially avascular (Figure 7J). 
Figure 6. Exogenous recombinant Sema3 (class 3 semaphorin)-F impairs Myc degradation and inhibits Thbs1 (thrombospondin 1) 
expression in in vitro differentiated visceral yolk sac (VYS) epithelial cells (EpCs). A, Mouse F9 teratocarcinoma stem cells differentiated 
in VYS EpCs express Sema3F receptor Nrp2, as revealed by immunofluorescence staining. B, Stimulation with exogenous rSema3F 
increases Myc expression and reduces Myc Thr58 phosphorylation in in vitro differentiated VYS EpCs derived from mouse F9 teratocar-
cinoma stem cells. C, rSema3F stimulation also decreases the expression of antiangiogenic Thbs1 protein in VYS EpCs derived from 
mouse F9 teratocarcinoma stem cells. D, The relative fluorescence intensity of Myc, Thr58 phosphorylated Myc, and Thbs1 was mea-
sured in VYS EpCs derived from mouse F9 teratocarcinoma stem cells stimulated or not with rSema3F. Data are mean±SEM. n=15 cell 
aggregates per condition pooled from 3 independent experiments. (***P<0.0001; *P<0.05, Student t test). Scale bars, 25 μm.
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Thus, abnormalities of Sema3a−/− Sema3f−/− yolk sac blood 
vessels (Figure 7J) were considerably more serious than those 
observed in either Sema3f−/− (Figure 1R, 1S, 1X, and 1Y) or 
Sema3a−/− (Figure 1T, 1U, 1Z, and 1AA) yolk sacs.
Discussion
The formation of properly patterned intraembryonic and 
extraembryonic blood vessel networks is crucial to develop-
ment of vertebrate organisms.1 By counteracting the activ-
ity of proangiogenic factors such as VEGFA, antiangiogenic 
Sema3 proteins, eg, Sema3A and Sema3E, play key roles in 
shaping blood vascular patterns of developing embryos.12 
Here, we unveil how, as a notable exception, Sema3F selec-
tively exerts an effective proangiogenic activity during extra-
embryonic, but not intraembryonic, vascular development. 
The defective vascularization of Sema3f-null yolk sacs phe-
nocopies the defects of Nrp1−/− Nrp2−/− embryos that have 
nearly avascular yolk sacs.37 In addition, we observed that 
Sema3f−/− placentas are also anemic (Results section and 
Discussion section in the online-only Data Supplement). 
Sema3F signaling mainly relies on Nrp2 coreceptor.6 
However, in the absence of Nrp2, Sema3F can also signal 
via Nrp138 and dissociation constants for Sema3F binding 
to Nrp1 and Nrp2 are 1.1 and 0.09 nmol/L, respectively.39 
Altogether, our and previous data suggests that both Nrp1 
and Nrp2 may be required to allow Sema3F-promoting extra-
embryonic vascular development.
In Sema3f−/− yolk sacs, we observed a significant down-
regulation of Myc, a transcription factor that regulates the 
expression of several gene sets, such as those promoting devel-
opmental23 and tumor29 angiogenesis. Myc protein levels are 
regulated by GSK3 that, by phosphorylating Myc on Thr58, 
generates a phosphodegron that enables Fbw7 ubiquitin ligase 
binding, Myc ubiquitylation, and proteasomal degradation.25 
Notably, as previously reported in cultured cells,25 we also 
found that in Sema3f−/− yolk sacs, the drop in Myc protein 
abundance was combined with an increased Myc Thr58 phos-
phorylation in Nrp2-expressing VYS EpCs. Fittingly, we also 
observed that the treatment of in vitro differentiated Nrp2+ 
VYS EpCs with exogenous Sema3F decreases Myc Thr58 
phosphorylation, thus promoting Myc accumulation. In EnCs, 
Sema3F inhibits the phosphatidylinositol 3 kinase-depen-
dent activation of Akt22 that is known to phosphorylate and 
inactivate GSK3.40 It seems that instead in VYS EpCs auto-
crine/paracrine Sema3F, by either activating a GSK3 kinase 
(such as Akt, p90RSK, p70S6K, and PKA) or inhibiting a 
GSK3-phosphatase (eg, PP2A), impairs the GSK3-dependent 
phosphorylation of Myc on Thr58 and its ensuing degrada-
tion. Further work is needed to establish the diverse molecular 
mechanisms by which Sema3F may activate or inhibit GSK3 
function in different cell types.
MiRNAs are central regulators of cardiovascular devel-
opment, and Myc promotes the transcription of the miR-
17/92 cluster,26,27 whose members miR-18a and miR-19b-1 
target the angiogenesis inhibitor Thbs1 hence promoting 
blood vessel formation.30,31 We revealed how lack of Sema3F 
results in reduced miR-18a and miR-19b-1 gene transcrip-
tion, increased Thbs1 protein in VYS EpCs, and dramatically 
reduced VEGF-R2 tyrosine phosphorylation in vascular EnCs 
of E9.5 Sema3f−/− yolk sacs. Consistently, we also observed 
that exogenous Sema3F strongly inhibits the expression of 
Thbs1 protein in in vitro differentiated Nrp2+ VYS EpCs.
Our findings unveil a reciprocal cellular cross-talk 
that supports extraembryonic angiogenesis in the yolk sac 
(depicted in Figure VI in the online-only Data Supplement). 
In VYS EpCs, Sema3F, which is produced by both VYS EpCs 
and EnCs, signals to counteract the GSK3-driven degradative 
phosphorylation of Myc on Thr58, thus fostering the Myc-
dependent transcription of proangiogenic miR-17/92 cluster 
members that in turn inhibit the synthesis of the antiangio-
genic protein Thbs1 in VYS EpCs themselves, finally allow-
ing EnCs to be elicited by VEGFA, which is also secreted by 
VYS EpCs and required for yolk sac vascularization.41 In sum, 
we provide evidence that the extraembryonic proangiogenic 
activity of Sema3F relies on the Myc-dependent inhibition of 
the antiangiogenic protein Thbs1, which in turn is an effec-
tive inhibitor of VEGF signaling.33 Indeed, the Thbs1 receptor 
CD36 has been shown to physically interact with VEGF-R2 
and hamper its ligand-induced phosphorylation and biologi-
cal activity on EnCs.28,33 Mechanistically, it was reported that 
Thbs1 binding to CD36 recruits the SHP-1(Src homology 2 
domain–containing protein tyrosine phosphatase-1) to the 
CD36–VEGF-R2 complex, where SHP-1 dephosphorylates 
and inactivates VEGF-R2 proangiogenic signaling.34
In light of the fact that another Nrp2-binding semapho-
rin, that is, SEMA3B, was already suggested to be involved 
in human preeclampsia,42 our finding that Sema3f knockdown 
severely impairs placentas development and vascularization 
suggests that an abnormal expression of Sema3F might be 
implicated in placenta vascular malformations and malignant 
tumors (Results section, Discussion section, and Figure II in 
the online-only Data Supplement).
Table 3. Genotypes of Progeny from Sema3a+/−/Sema3f+/− Intercrosses
 Total 3a+/+/3f+/+ 3a+/−/3f+/− 3a+/−/3f+/+ 3a+/+/3f+/− 3a−/−/3f+/− 3a+/+/3f−/− 3a+/−/3f−/− 3a−/−/3f+/+ 3a−/−/3f−/−
Term Pups 405 10.1% (41) 35.8% (145) 21.4% (87) 17.3% (70) 3.5% (14) 3.5% (14) 4.9% (20) 3.5% (14) 0% (0)




 6.25% 25% 12.5% 12.5% 12.5% 6.25% 12.5% 6.25% 6.25%
Heterozygous Sema3a+/−/Sema3f+/− mice were intercrossed, and the progeny was analyzed. No adult double Sema3a Sema3f-knockout mice were observed after 
genotyping the offspring (n=405). Timed mating revealed an embryonic lethality until E9.5, and only the 3.6% (n=387) were Sema3a−/−/Sema3f−/− at E9.5. This 
percentage is the half than the Mendelian expected ratio. Sema3 indicates class 3 semaphorin.
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As previously reported in zebrafish,9 chick,10 and mouse 
embryos,8,17–19 here we further substantiate how, differently 
from Sema3F, Sema3A is a crucial driver of embryonic vascular 
morphogenesis. Our findings that ≈80% of Sema3a-knockout 
embryos die in utero and display a strong growth retardation 
compared with wild-type embryos reconcile previous appar-
ently contradicting observations that, based on age and stage 
matching between wild-type and Sema3a-null embryos, con-
cluded that Sema3A does not influence embryonic angio-
genesis.43 Furthermore, we establish how Sema3A similarly 
controls the remodeling of the yolk sac vasculature.
We found that in Sema3a-knockout mice, embryonic and 
extraembryonic blood vessels develop but display severe 
defects remodeling into an optimized hierarchically branched 
mature vascular tree. On the contrary, in Sema3f-knockout 
mice, embryonic blood vessels are effectively remodeled 
into a mature and functional tree, whereas vascularization 
of extraembryonic tissues is strongly reduced and poorly 
branched. It seems that, compared with Sema3f−/− yolk sacs, 
the simultaneous knockdown of Sema3a and Sema3f gene 
further impairs the vascularization of the yolk sac that, until 
E12.5, is the primary means of nutrient, gas, and waste 
exchange for the mouse embryo.3 Therefore, our findings 
suggest that the further dramatic impairment of embryonic 
vascular remodeling observed in Sema3a/Sema3f-double 
knockout embryos, compared with Sema3a−/− embryos, is 
conceivably because of the severe disruption of the vascula-
ture of the yolk sac, which constitutes the main nutrient and 
gas exchange organ between mother and embryo. Our data 
are in agreement with the fact that the yolk sac constitutes the 
first main nutrient and gas exchange organ between mother 
and embryo and with previous observations that mutations 
causing severe disruption yolk sac blood vessel formation are 
lethal and result in severe defects in embryo development.44–51 
Finally, the severe disruption of the embryonic vasculature 
observed in Sema3a/Sema3f-double knockout phenocopy the 
previously described vascular phenotype of double targeted 
Nrp1−/− Nrp2−/− embryos.37
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Highlights
• Sema3 (class 3 semaphorin)-F is a novel extraembryonic proangiogenic factor.
• Sema3F inhibits the degradative phosphorylation of Myc on Thr58 in visceral yolk sac epithelial cells, both in vivo and in vitro.
• In the mouse yolk sac, Sema3F fosters the transcription of members of the Myc-dependent proangiogenic miR-17/92 cluster.
• Sema3F inhibits the synthesis of the Myc target and antiangiogenic protein thrombospondin 1 in visceral yolk sac epithelial cells, both in vivo 
and in vitro.
• Sema3F promotes the phosphorylation of vascular endothelial growth factor receptor 2 in yolk sac vascular endothelial cells.
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Materials and Methods 
Animals 
C57Bl/6 mice carrying the Sema3a-null allele1 or C57Bl/6;129P2/OlaHsd carrying the Sema3f-
null allele 2 were previously described and respectively obtained from the RIKEN BioResource 
Center (strain name: semaphorin III/D-null targeting mice; code no. RBRC01104) and The 
Jackson Laboratory (strain name: B6;129P2-Sema3ftm1Mom/MomJ; code no. 006710), 
respectively. A panel of 141 validated SNP (single nucleotide polymorphism) markers spaced 
evenly throughout the genome and covering all autosomes and the X chromosome3, 4 was 
employed to define the percentage of C57Bl/6 and 129P2/OlaHsd genetic background of our 
Sema3f +/- mouse colony. The analysis showed that the genetic background of the Sema3f +/- 
mouse strain employed in our study was 91.5 ± 0.01413% C57Bl/6 and 8.5 ± 0.01413% 
129P2/OlaHsd (Suppl. Fig. S1). 
Single heterozygous mice (n=460 for Sema3a +/- and n=465 for Sema3f +/-) were bred to 
examine the progeny of these mutants. To obtain double Sema3a +/-/Sema3f +/- heterozygotes, 
single Sema3a +/- and Sema3f +/- mice were bred and a total of 405 pups were examined at birth. 
Genotyping was carried out by genomic PCR (polymerase chain reaction) of DNA samples 
extracted from tail tips following standard protocols. To obtain mouse embryos of defined 
gestational ages, heterozygous female mice in estrus were placed with heterozygous males in the 
evening. The morning of vaginal plug detection was defined as 0.5 dpc (days post-coitum). 
Embryos and yolk sacs were carefully dissected free of maternal tissue. Genomic DNA from 
yolk sac or embryos was analyzed by PCR (polymerase chain reaction) to determine the 
genotype. All animal procedures were approved by the Ethical Commission of the University of 
Torino and by the Italian Ministry of Health in compliance with the international laws and 
policies. 
 
Isolation of Embryos and Yolk Sacs and Whole Mount Immunofluorescence Staining 
Embryos and yolk sacs were removed from pregnant females at 9.5 and 10.5 dpc (days post-
coitum) and examined. For whole-mount immunofluorescence staining, freshly dissected tissues 
were fixed for 2 hours in 4 %(PFA) paraformaldehyde  at 4°C, washed in PBT (PBS - 
phosphatase buffered solution-, 0.1 % Tween 20) and subjected to dehydration in increasing 
methanol concentration (50 %, 80 % methanol/PBT, 100 % methanol) followed by rehydration 
in decreasing methanol concentration (80 %, 50 % methanol/PBT, PBT). After washing in Pblec 
(PBS - phosphatase buffered solution - pH 6.8, 1 % Tween 20, 1mM CaCl2, 1mM MgCl2, 
0,1mM MnCl2) embryos and yolk sac were incubated overnight with Rat-anti Endomucin (clone 
V.7C7 Santa Cruz sc-65495) diluted 1:20 in Pblec. After 5 washes in PBT, tissues were 
incubated overnight at 4°C with goat anti-rat Alexa 555 (Invitrogen) diluted 1:400 in PBT, 
followed by washing in PBT and post-fixation in 2 % PFA before analysis. Stained embryos and 
yolk sacs were photographed either and analyzed with a Leica TCS SP2 AOBS confocal laser-
scanning microscope (Leica Microsystems). 
 
In Vitro Generation of Model of VYS (visceral yolk sac ) Eps (epithelial cells) From F9 
Testicular Teratocarcinoma Stem Cells 
Mouse testicular epithelium F9 cells (ATCC CRL-1720) were differentiated in VYS (visceral 
yolk sac) Eps (epithelial cells) as previously described5, 6. Briefly, F9 cells were grown in 
Dulbecco’s Modified Eagle’s Medium (D5546, Sigma Aldrich) supplemented with 10% of Fetal 
Bovine Serum (ECS0180D, EuroClone) and seeded in cell culture dishes, pre-coated with 0.1% 
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gelatin from porcine skin (G9136, Sigma Aldrich). F9 cells were differentiated into VYS 
(visceral yolk sac ) Eps (epithelial cells), growing them in suspension in Bacteriological Petri 
dishes (#351029, Falcon, Corning Life Sciences Catalog), in presence of 50nmol/l Retinoic Acid 
(R2625, Sigma Aldrich) for 14 days. Culture medium was replaced every 2 days. After 14 days 
of culture, cells were collected in tubes, allowed to precipitate by gravity and stimulated or not 
with 800ng/ml recombinant mouse Sema3F (Semaphorin 3F), for different time points. 
 
Immunofluorescence and Confocal Microscopy Quantification 
Yolk sacs from E9.5 and mouse embryos were fresh frozen in OCT and 10μm-thick sections 
were cut using a Leica CM1900 cryostat. Sections were air-dried and fixed with Zinc Fixative 
(6,05g Tris, 0,35g Ca(C2H3O2)2, 2,5g Zn(C2H3O2)2, 2,5g ZnCl2, 3,8 ml HCl 37 %) for 10 minutes 
at room temperature. Tissues were stained by employing the following primary antibodies: anti-
Semaphorin 3F (ab39956, 1:100, Abcam), anti- Neuropilin-2 (AF567, 1:100, R&D Systems), 
anti-Myc (phospho-Thr58) (ab28842, 1:100, Abcam), anti-Myc (#5605, 1:100, Cell Signaling), 
anti-Thrombospondin-1 (LS-C137099, 1:100, Lifespan Biosciences), anti-Endomucin (clone 
V.7C7 Santa Cruz sc-65495), anti-Snail1 (sc-28199, 1:100, Santa Cruz Biotechnology) and anti-
Cytokeratin 8/18 (GP11, PROGEN Biotechnik GmbH). To reveal phosphorylated VEGF-R2 in 
vascular EnCs, sections were incubated O/N at 4°C with purified Rabbit monoclonal anti-
phospho-VEGF-R2 (Tyr1175) (clone 19A10, cat # 2478, Cell Signaling, dil. 1:100), anti-VEGF-
R2 (cat # 55B11, Cell Signaling, dil. 1:100), anti-Thrombospondin-2 (LS-C393305, 1:100, 
Lifespan Biosciences), anti-Semaphorin 3A (cat #AF1250, R&D Systems, dil. 1:50) and purified 
Rat anti-endomucin (clone V.7C7 Santa Cruz sc-65495); anti-Rat Alexa Fluor-488 and anti-
Rabbit Alexa Fluor-555 (dil. 1:400, Molecular Probes) were employed as secondary antibodies. 
All tissue immunofluorescence images were captured by using a Leica TCS SP2 AOBS 
confocal laser-scanning microscope (Leica Microsystems) and by maintaining the same laser 
power, gain and offset settings. To determine the expression level of Myc and Thbs-1 proteins, 
we analyzed at least 2 non-overlapping fields for each yolk sac (n=6). Quantification was done 
by calculating the ratio between the red channel and the blue channel (Dapi - 4',6-diamidino-2-
phenylindole) by means of ImageJ software. Data are presented as relative fold change of the 
total amount of Myc or Thbs-1 (thrombospondin 1) fluorescence normalized on the total cell 
number. Colocalization analysis was performed using plugins embedded in the visualization and 
analysis software ImageJ. Analysis was performed on a similar-sized symmetrical  ROI (region 
of interest) selected for each dye. Background levels were subtracted from each ROI (region of 
interest) before calculating the degree of colocalization. 
VYS (visceral yolk sac) Eps (epithelial cells) generated in vitro from F9 cells were either 
fixed in 4% paraformaldehyde for 20 min at room temperature or in cold methanol for 10 min at 
room temperature and permeabilized in PBS (phosphatase buffered solution) 0.5% Triton X-100 
for 30 min or fixed in cold acetone for 2 min at room temperature and permeabilized in PBS 
(phosphatase buffered solution) 0.5% Triton X-100 for 15 min, in constant rotation. Cells were 
incubated with primary antibodies, diluted in PBS (phosphatase buffered solution) 0.2% Triton 
X-100, 1% DS (Donkey Serum) and maintained in constant rotation over-night at 4°C. Cells 
were washed with PBS (phosphatase buffered solution) 0.2% Triton X-100, 1% DS and 
incubated with the appropriate Alexa-Fluor-tagged secondary antibody for 2 hours at 4°C in 
constant rotation, protected from light. Cells were washed with PBS (phosphatase buffered 
solution) 0.2% Triton X-100, 1% DS and PBS (phosphatase buffered solution), included in 
Fluoromount-G Slide Mounting Medium (Cat. No. 0100-01, SouthernBiotech) and mounted on 
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microscope slides. Cells were analyzed by using a Leica TCS SP8 AOBS confocal laser-
scanning microscope (Leica Microsystems). 
 
RNA Preparation and Quantitative RT-PCR (quantitative reverse time polymerase chain 
reaction) 
Littermate’s embryos and yolk sacs (E9.5) were dissected and stored in RNAlater® reagent 
(QUIAGEN) over night at 4°C and then stored at -80°C. Total RNA was extracted using 
TRIzol® (Gibco-BRL; Grandisland, NY, USA) according to the manufacturer’s 
recommendations. RNA amount was measured with a NanoDrop™ 1000 spectrophotometer 
(Thermo Scientific) under 260 nm. Two micrograms of total RNA was reverse transcribed to 
first strand complementary DNA (cDNA) using Random Primers and High-Capacity cDNA 
Reverse Transcription Kit (4368814 Life Technologies). cDNA was analyzed by TaqMan® gene 
expression single assay (Life technologies) by using the probe for Vegfa (Mm00437306_m1), 
Thbs1(Mm01335418) and ABI PRISM® 7900HT Fast Real-Time PCR System (Applied 
Biosystems). The data where analyzed by SDS and RQ Manager Software to obtain a relative 
quantification based on the arithmetical equation 2-ΔΔCt, in which ΔΔCt is the normalized signal 
level in a sample relative to the normalized signal level in the corresponding calibrator sample. 
mRNAs were normalized to the housekeeping tbp and the fold changes (RQ) were calculated 
compared with the ΔCt of wild type embryos and yolk sacs. 
 
Yolk Sac miRNAs Extraction and Expression Profiling 
Six E9.5 yolk sacs for each experimental group (wild type, Sema3f -/-, and Sema3a -/- embryos) 
were pooled and used for miRNAs extraction. MiRNAs were isolated using the mirVana™ 
miRNA Isolation Kit (Ambion) according to the manufacturer’s instruction. The purity and 
quantity of RNAs were assessed by means of the Nanodrop™ 1000 spectrophotometer (Thermo 
Scientific). All samples were diluted to have a total of 2 μg in a final volume of 10μl. Samples 
were used immediately or stored at -80°C for future use. Mouse miRNAs for mmu-miR-18a and 
mmu-miR-19b-1 were analyzed with technical triplicate by using quantitative RT-PCR (reverse 
transcription polymerase chain reaction) with specific probes.  
 
Histology and Immunohistochemistry of Mouse Placentas. 
10.5 days of gestational age placentas were collected, fixed in buffered formalin and embedded 
in paraffin. Serial sagittal sections of 5 μm were sectioned using a Leica 2135 microtome. Every 
5th slide was deparaffinized and subjected to graded rehydration through xylene, 100 %, 95 %, 
70 % ethanol and then stained with hematoxylin and eosin (H&E) as previously described 
(Fisher et al., 2008). Slides were examined in order to find the midpoint of the placenta (site of 
umbilical attachment), which is used as the major reference point for comparisons between 
mutants and wild type littermates. For immunostaining, the same formalin-fixed placentas were 
sectioned at 3μm and slides were incubated with 3 % H2O2 for 20 minutes to suppress the 
endogenous peroxidase activity. After 3 washes in Phosphatase Buffered Solution (PBS), slides 
were immersed in diluted Dako Target Retrieval Solution (S1699) and heated in a water bath 
(95-96°C). Sections were probed over night with rat-anti Endomucin (clone V.7C7 Santa Cruz 
sc-65495) diluted 1: 50 in blocking solution (Dako, X0909). After 3 washes in PBS, slides were 
incubated for 1 hour at room temperature with the polyclonal rabbit anti-rat immunoglobulins 
conjugated with horseradish peroxidase (Dako). The signal was detected by using the Dako AEC 
(K3461) and the slides were mounted with the Dako Mounting Medium (CS703). Images were 
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captured with a BX-60 microscope (Olympus) equipped with a color Qicam Fast 1394-digital 
CCD camera 12 bits (QImaging Corp.) and analyzed by the Image-Pro Plus 6.2 Software (Media 
Cybernetics). 
 
Blood vessels branching analysis 
Quantification of vessel branching was obtained by analyzing the placenta of wild type (n=3), 
Sema3a -/- (n=3), and Sema3f -/- (n=3) mice. At least three 10x power field immunohistochemical 
images were analyzed for each sample. Images were processed by means of ImageJ open source 
software (http://imagej.net/Home). Immunohistochemically stained blood vessel networks were 
separated by means of the ImageJ color deconvolution plugin. The resulting black and white 
images were imported into the imaging software winRHIZO Pro (Regent Instruments Inc.) and 
analyzed as previously described 7 
 
Statistical Analysis 
Results of all experiments are expressed as mean ± SD or SEM. Statistical analyses were 
performed using 2-tailed heteroscedastic Student t-test using GraphPad Prism software. A p 
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Supplementary Results 
Since Sema3f-null yolk sacs were poorly vascularized, next we analyzed the vascularization 
of the placenta that constitutes the second crucial extraembryonic organ in the control of 
nutrient and gas exchanges. In the mouse, placenta development, is usually complete by 
E12.5 1. Proceeding from the fetal to the maternal side, the mature placenta consists of the 
labyrinth, the spongiotrophoblast, and the uterine decidua 2. Due to the abundant 
vascularization, when viewed externally from the chorion side, the labyrinth of E9.5 wild 
type mice placentas was bright red and the labyrinth edge was easily discernible (Figure IIA). 
While placentas of E9.5 Sema3anull mice did not exhibit gross alteration (Figure IIG), those 
of Sema3f -/- mice were instead very anemic (Figure IID), suggesting the likely presence of 
labyrinth abnormalities. Indeed, if compared to wild type (Figure IIB) and Sema3a -/- (Figure 
IIH) counterparts, in E10.5 Sema3f -/- placentas (Figure IIE) all layers were present, but the 
labyrinth layer thickness was almost halved, the maternal blood filled lacunae were absent, 
and the spongiotrophoblast layer was markedly thinner. Accordingly, Sema3f -/- (Figure IIF), 
but not wild type (Figure IIC) and Sema3a -/- (Figure III) placentas displayed a dramatic 
reduction in endomucin-stained labyrinth blood vessels (Figure IIF). Notably, in line with the 
effect of Sema3A (Semaphorin 3A) in regulating blood vessel remodeling, the branching of 
the vasculature of Sema3a -/-, but not Sema3f -/- placentas was significantly increased 
compared to controls (1.8-fold, Figure IIJ). 
 
Supplementary Discussion 
Several studies previously investigated the role of Sema3F (Semaphorin 3F) in peripheral and 
central nervous system development 3-9. More recently, Uchida and colleagues highlighted 
the role of Sema3F as an inhibitor of lymphatic vessel development in the mouse embryo 10. 
Here, we report instead for the first time the analysis of the role of Sema3F in the 
development of blood vessels in the murine embryo and associated extraembryonic organs. 
We discovered that, differently from all the inhibitory effects described so far either in the 
nervous or in the lymphatic system, surprisingly and unpredictably Sema3F acts as a key 
promoter of developmental angiogenesis only in extraembryonic organs, namely yolk sac and 
placenta, with potential implications for life-threatening human diseases, such as pre-
eclampsia. Indeed, Zhou and colleagues 11 previously reported how placental 
cytotrophoblasts of human preeclampsia patients express abnormally high levels of Nrp2-
binding SEMA3B (SEMAPHORIN 3B) that, by inhibiting cytotrophoblasts motility and 
angiogenesis, participates to the pathogenesis of this disease. We provide evidence of how 
Nrp2 (Neuropilin 2)-binding Sema3F activates instead crucial signals that promote 
extraembryonic angiogenesis and placental development. Altogether these findings suggest 
that Nrp2-binding SEMA3B and SEMA3F (SEMAPHORIN 3F) proteins may be involved in 
both physiological and pathological placental development and may represent actionable 






Supplementary Figure Legends 
 
Figure I. SNP (single nucleotide polymorphism) characterization of the genetic background 
of the Sema3f heterozygous strain. The genomic DNA of 11 Sema3f+/- mice (Test01-11) was 
analyzed to determine the percentage of C57BL/6 and 129P2/OlaHsd genetic background by 
using a panel of 141 validated SNP markers (SNP_ID) spaced evenly throughout the genome 
and covering all autosomes and the X chromosome. Genomic DNA of pure C57BL/6 (Ctl01) 
and 129P2/OlaHsd (Ctl02) mice as well as that of a heterozygous C57BL/6 / 129P2/OlaHsd 
(Ctl03) mice were employed for control purposes. The analysis showed that the genetic 
background of the Sema3f+/- mouse strain was 91.5 ± 0.01413% C57BL/6 and 8.5 ± 
0.01413% 129P2/OlaHsd. 
 
Figure II. Sema3 (class 3 semaphorin)-F is required for placental blood vessel formation. 
Stereomicroscopic images of E10.5 wild type (A), Sema3f -/ - (D) and Sema3a -/- (G) 
placentas. On the chorion side, the bright red edge of the labyrinth is easily discernible in 
E10.5 wild type and Sema3a -/-, but not Sema3f -/- placentas that are poorly vascularized. 
Hematoxylin-eosin stained histological sections of placental tissues of E10.5 wild type (B), 
Sema3f -/- (E) and Sema3a -/- (H) placentas. If compared to wild type (B) and Sema3a -/- (H) 
samples, Sema3f -/- placentas (E) are characterized by a significant reduction in size of Sp 
(spongiotrophoblast) and La (labyrinth) layers. Endomucin immunohistochemical staining 
reveals that wild type (C), but not Sema3f -/- placentas (F) display an extensive and 
vascularized labyrinth network. While no gross alterations in the vessels density were 
observed in the labyrinth layer of Sema3a -/- placentas (I). Analysis of endomucin-stained 
placenta revealed a 1.8 increase in blood vessel branching in Sema3a-/- (n=3), but not Sema3f 
-/- mice (n=6) (J). GI (giant cells into the uterin decidua). Scale bars, 100 µm (A, D, G) and 
200 µm (B, C, E, F, H, I). ** p<0.001. 
 
Figure III. A, Sema3(class 3 semaphorin)-A expression is not affected in Sema 3f-/- yolk sacs 
and it largely co-localizes with endomucin+ EnCs (endothelial cells). B, Bar graph shows the 
percentage of Sema3A colocalization with endomucin both in wild type and Sema 3f-/- yolk 
sacs. C, In E9.5 embryos, Sema3F is mainly expressed by endomucin+ EnCs of both wild 
type and Sema3a -/- embryos. As expected, Sema3F protein is undetectable in Sema 3f-/- 
embryos. Scale bars, 100 µm. D, Bar graph shows the percentage of Sema3F co-localization 
with endomucin both in wild type and mutant embryos. 
 
Figure IV. Sema3 (class 3 semaphorin)-F promotes Thbs1 (thrombospondin 1) gene 
transcription in the mouse yolk sac while does not affect Vegfa transcription. A, RT-PCR 
(reverse transcription polymerase chain reaction) on wild type and Sema3f -/- yolk sacs did 
not display a significant difference in Vegfa mRNA transcription level. (n=6). B, RT-PCR 
(reverse transcription polymerase chain reaction) analysis reveals how, compared to wild type 
yolk sacs, Thbs1 mRNA increases in Sema3f -/- yolk sacs and decreases in  
Sema3a -/- yolk sacs (* p<0.05). 
 
Figure V. Sema3f -knockdown does not affect Thbs2 (thrombospondin 2) protein expression. 
A Quantification of immunofluorescence analysis of E9.5 yolk sacs showed that Thbs2 
protein is mainly expressed in CK8/18 (cytokeratin 8/18) + VYS (visceral yolk sac) EpCs 
(epithelial cells). No differences in Thbs2 expression were observed in Sema3f -/- yolk sacs 
compared to wild type controls. B, Bar graph shows the percentage of Thbs2 colocalization 
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Chromosome-bp C57BL/6J 129S1/SvImJ Test01 Test02 Test03 Test04 Test05 Test06 Test07 Test08 Test09 Test10 Test11 Ctl01 Ctl02 Ctl03
01‐005230167‐M C T T T/C T T/C C C C C C C C T T/C
01‐026072256‐M G T G G G G G G G G G G G G T T/G
01‐046003967‐M A C A A A A A A A A A A A A C C/A
01‐066294607‐M A G G/A A A A A A A A A A A A G G/A
01‐086182722‐M A G A A A A A A A A A A A A G G/A
01‐102073421‐M G C G G G G G G G G G G G G C C/G
01‐143006008‐M A G A A A A A A A A A A A G G/A
01‐162977516‐M G A G G G G G G G G G G G G A A/G
01‐185013929‐M C G C C C C C C C C C C C C G G/C
02‐003179310‐M G A G G G G G G G G G G G A A/G
02‐020551513‐M A G A A A A A A A A A A A G G/A
02‐040184477‐M C T C C C C C C C C C C C C T T/C
02‐061161692‐M T C T T T T T T T T T T T T C C/T
02‐078062303‐M T G T T T T T T T T T T T T G G/T
02‐104075364‐M G C G G G G G G G G G G G G C C/G
02‐119931810‐M A T T/A T/A T T/A A A A A A A A T T/A
02‐139603599‐M T A T T T T T T T T T T T T A A/T
02‐160869410‐N T C C T/C T/C C T/C T T T T T T T C T/C
02‐179086475‐M G T G G G G G G G G G G G T T/G
03‐011350737‐M G C G G G C/G G G C/G G G G G G C C/G
03‐031231243‐M T C T C/T T C/T C/T T T T T T T C C/T
03‐062390782‐M G A A A A A A A A/G A A A A G A A/G
03‐082192100‐M G A A A/G A/G A A A/G G A/G A/G A A G A A/G
03‐102189723‐M T G
03‐119173143‐M G A G G G G G G G G G G G G A A/G
03‐139158872‐M G A G G G G G G G G G G G G A A/G
03‐160287200‐M G A G A/G A/G G A/G A A A A A A G A A/G
04‐003163167‐M G T G G G G G G G G G G G G T T/G
04‐024192594‐M T A T T T T T T T T T T T T A A/T
04‐046000627‐M A T A A A A A A A A A A A A T T/A
04‐067425585‐N T C T T T T T T T T T T T T C C/T
04‐086758585‐N A G A A A A A A A A A A A A G G/A
04‐106314110‐M C A C C C C C C C C C C C A A/C
04‐125988404‐M T A T T T T T T T T T T T T A A/T
04‐145870512‐M C G C C C C C C C C C C C C G G/C
05‐009080098‐M G A G G G G G G G G G G G G A A/G
05‐029064177‐N A G A A A A A A A A A A A A G A/G
05‐049570566‐N G T G G G G G G G G G G G G T T/G
05‐069043957‐M A G A A A A A A A A A A A A G G/A
05‐088937905‐M G A G G G G G G G G G G G G A A/G
05‐107871207‐M G A G G G G G G G G G G G G A A/G
05‐128944450‐M T C T T T T T T C/T T T T T T C C/T
05‐130950804‐M A C A A A A A A A A A A A C C/A
05‐149044358‐M C A C C C C C C C C C C C C A A/C
06‐003167392‐M C T C C C C C C C C C C C C T T/C
06‐020075608‐M T G T T T T T T T T T T T T G G/T
06‐036801292‐N T C T T T T T T T T T T T T C T/C
06‐056162117‐M A G G A A G/A A A A A A A A A G G/A
06‐076285738‐M T A T T T T T T T T T T T T A A/T
06‐084009195‐M A G A A A A A A A A A A A A G G/A
06‐122941044‐M T A T T T T T T T T T T T T A A/T
06‐146079591‐M A C A A A A A A A A A A A A C C/A
07‐004201219‐N A G A A A A A A A A A A A A G G/A
1
07‐022997618‐M C T C C C C C C C C C C C C T T/C
07‐041032053‐M G A G G G G G G G G G G G G A A/G
07‐061010042‐M C T C C C C C C C C C C C C T T/C
07‐080974545‐M T G T T T T T T T T T T T G G/T
07‐102009856‐M C T C C C C C C C C C C C C T T/C
07‐124090029‐M A G A A A A A A A A A A A A G G/A
08‐003089774‐M T C T T T T T T T T T T T T C C/T
08‐022074356‐M A G A A A A A G/A A G/A G G/A A G G/A
08‐041947937‐M T A T T T T T T A A/T A/T A T A A/T
08‐067470102‐N G C G G G G G G G G G G G G C G/C
08‐086985036‐M C T C C C C C C C C C C C C T T/C
08‐107088585‐M A G A A A A A G/A A A A A A A G G/A
08‐123021323‐M T C T T T T T T T T T T T T C C/T
09‐005920375‐M G A G G G G G G G G G G G G A A/G
09‐027092605‐M T G T T T T T T T T T T T T G G/T
09‐046117336‐N A G A A A A A A A A A A A A G G/A
09‐066767939‐N G A G G G G G G G G G/A G/A G G A G/A
09‐086008489‐M A C A A A A A A C/A A A A A A C C/A
09‐106854728‐M C T C C C C C C C C C C C C T T/C
09‐125082704‐M G A G G G G G G G G G G G G A A/G
10‐006702399‐N A T A A A A A A A A A A A A T A/T
10‐027070647‐M G T G G G G G G G G G G G G T T/G
10‐045078228‐M A G A A A A A A A A A A A A G G/A
10‐053898997‐M G C G G G G G G G G G G G G C C/G
10‐092128703‐M G A G G G G G G G G G G G G A A/G
10‐107333522‐M C T T/C C C T T/C C C C C C C C T T/C
10‐127241589‐M G A G G G G G G G G G G G G A A/G
11‐004367508‐M G A A/G A/G G A/G A/G G G G G G G G A A/G
11‐024515722‐M G A G G G G G G G G G G G G A A/G
11‐044333996‐M A G A A A A A A A A A A A A G G/A
11‐063538723‐N G A G G G G G G G G G G G A G/A
11‐083523677‐M G C G G G G G G G G G G G G C C/G
11‐104171075‐M A G A A A A A A A A A A A A G G/A
11‐108428031‐M T C T T T T T T T T T T T T C C/T
11‐111226923‐M A C C/A C/A A C/A C/A A A A A A A C C/A
11‐122195777‐M C T C C C C C C C C C C C C T T/C
12‐003567042‐M G T G G G G G G G G G G G G T T/G
12‐024149189‐N T C T T T T T T T T T T T T C T/C
12‐045157254‐N C T C C C C C C C C C C C T T/C
12‐065480669‐M C T C T T/C C T/C T T T T T T C T T/C
12‐084289638‐M C A A C A/C A/C A/C A/C A/C A/C A/C A C A A/C
12‐099072867‐M T C T T T C/T T C/T T C/T T C/T T T C C/T
12‐113315003‐M C G C C C C C C C C C C C G G/C
13‐009820324‐M A G A A A A A A A A A A A G G/A
13‐030913320‐M T C T T T T T T T T T T T T C C/T
13‐052501751‐N G A G G G G G G G G G G G A A/G
13‐071928027‐M C A C C C C C C C C C C C C A A/C
13‐091042598‐M G A G G G G G G G G G G G G A A/G
13‐113057436‐M A G A A A A A A A A G/A G/A A A G G/A
14‐005055006‐M T A T T T T T T T T T T T T A A/T
14‐024063411‐M A G A A A A A A A A A A A A G G/A
14‐043974306‐M T A T T T T T T T T T T T T A A/T
14‐063983099‐M A G A A A A A A A A A A A A G G/A
14‐074468555‐M G A G G G G G G G G G G G G A A/G
14‐093080383‐M G A G G G G G G G G G G G G A A/G
14‐112205439‐N G A G G G G G G G G G G G G A A/G
15‐003094890‐M A G G/A G G/A G/A G/A A A A A A A A G G/A
15‐020280219‐M G T G G G G G G T/G G G G G G T T/G
15‐039906196‐M G A G G G A/G G G A/G G G G G G A A/G
15‐059754938‐N C T T/C C T/C T C C C C C C C C T T/C
15‐080211114‐N A G A/G A A/G A/G A/G A A A A A A A G A/G
2
15‐098621793‐N C T C C C/T C/T C/T C C C C C C C T C/T
16‐005053446‐C G T T G G T/G T/G T/G G T/G G G G G T T/G
16‐019621494‐C A G A/G A A A/G A/G A/G A G A/G A/G A/G A G A/G
16‐037994236‐C G A G/A G A G G/A G/A G/A G/A G G/A G A G/A
16‐057482753‐C A G A A A/G A A A/G G A/G A/G A A/G A G A/G
16‐075684315‐C T C T/C T T T/C T T/C C T/C T/C T T/C T C T/C
16‐095103053‐C C G C/G C C C/G C C C C C C C C G C/G
17‐004147924‐M A G A A A A A A A A A A A A G G/A
17‐024364775‐M G A G G G G G G G G G G G G A A/G
17‐043164647‐M G A G G G G G G G G G G G G A A/G
17‐066532305‐N T G T T T T G/T G/T G/T T T G/T G/T T G G/T
17‐086110517‐N G A G G G G G G G G G G G G A A/G
18‐005066417‐M T C T T T T T T T T T T T T C C/T
18‐030864114‐M T C C/T C C T T C/T C C/T T C/T T C C/T
18‐049391366‐N T C T C C T T/C T/C C C T/C T T/C T C T/C
18‐070565016‐N C T T/C T T T/C T T/C T/C T/C T/C T/C T/C C T T/C
18‐090060367‐M G T G G G G G G G G G G G G T T/G
19‐021081804‐M A G A G/A G/A A G/A G/A G/A A A A A A G G/A
19‐041909356‐M G A G G G G G A/G A/G G G G G G A A/G
19‐060030696‐N A G G/A G/A G G G/A G G/A G G/A A G/A A G G/A
X‐008280846‐M A G A A A A A A A A A A A A G G/A
X‐035414447‐M T C T T T T T T T T T T T T C C/T
X‐054650362‐N T A T T T T T T T T T T T T A A/T
X‐068494838‐M C T C C C C C C C C C C C C T T/C
X‐088983795‐M T C T T T T T T T T T T T T C C/T
X‐109677875‐M A G A A A A A A A A A A A A G G/A
X‐123551831‐M A G A A A A A A A A A A A A G G/A



























   
   
   











































Figure II. Sema3 (class 3 semaphorin)-F is required for placental blood vessel formation. Stereomicroscopic images of E9.5 wild type (A), 
Sema3f -/- (D) and Sema3a -/- (G) placentas. On the chorion side, the bright red edge of the labyrinth is easily discernible in E10.5 wild type 
and Sema3a -/-, but not Sema3f -/- placentas that are poorly vascularized. Hematoxylin-eosin stained histological sections of placental tissues 
of E10.5 wild type (B), Sema3f -/- (E) and Sema3a -/- (H) placentas. If compared to wild type (B) and Sema3a -/- (H) samples, Sema3f -/- placentas 
(E) are characterized by a significant reduction in size of Sp (spongiotrophoblast) and La (labyrinth) layers. Endomucin immunohistochemical 
staining reveals that wild type (C), but not Sema3f -/- placentas (F) display an extensive and vascularized labyrinth network. While no gross 
alterations in the vessels density were observed in the labyrinth layer of Sema3a -/- placentas (I). Analysis of endomucin-stained placenta revealed 
a 1.8 increase in blood vessel branching in Sema3a-/- (n=3), but not Sema3f -/- mice (n=6) (J). GI (giant cells into the uterin decidua).











































































































Figure III. A, Sema3 (class 3 semaphorin)-A expression is not affected in Sema3f-/- yolk sacs 
and it largely colocalizes with endomucin+ EnCs (endothelial cells). B, Bar graph shows 
the percentage of Sema3A colocalization with endomucin both in wild type and Sema3f-/- 
yolk sacs. C, In E9.5 embryos, Sema3F is mainly expressed by endomucin+ EnCs of both 
wild type and Sema3a-/- embryos. As expected, Sema3F protein is undetectable in Sema3f-/- 
embryos. Scale bars, 100 μm. D, Bar graph shows the percentage of Sema3F 
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Figure IV. Sema3 (class 3 semaphorin)-F promotes Thbs1 (thrombospondin 1) gene transcription in the mouse yolk sac while does not 
affect Vegfa transcription. A quantitative RT-PCR (reverse transcription polymerase chain reaction) on wild type and Sema3f -/- yolk sacs
did not display a significant difference in Vegfa mRNA transcription level. (n=6). B quantitative RT-PCR (reverse transcription 
polymerase chain reaction) analysis reveals how, compared to wild type yolk sacs, Thbs1 mRNA increases in Sema3f-/- yolk sacs 
















































Figure V. Sema3f-knockdown does not affect Thbs2 (thrombospondin 2) protein expression. 
A, Quantification of immunofluorescence analysis of E9.5 yolk sacs showed that Thbs2 protein is mainly 
expressed in CK8/18 (cytokeratin 8/18)+ VYS (visceral yolk sac) EpCs (epithelial cells). No differences in Thbs2 
expression were observed in Sema3f -/- yolk sacs compared to wild type controls. B, Bar graph shows the 
percentage of Thbs2 (thrombospondin 2) colocalization with endomucin, CK8/18, and Snail1 both in wild 
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